Summary

for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion

Description

Summary

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

Official Title

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)

Keywords

Systemic Lupus ErythematosusSLELupus Erythematosus, SystemicBaricitinib

Eligibility

For people ages 18 years and up

Inclusion Criteria:

  • Have completed the final treatment study visit of an originating study, such as study JAHZ (NCT03616912) or Study JAIA (NCT03616964).

Locations

  • University of California - San Diegonot yet accepting patients
    La JollaCalifornia92037United States
  • Office: Dr Robin K Dorenot yet accepting patients
    TustinCalifornia92780United States
  • Talbert Medical Groupnot yet accepting patients
    Huntington BeachCalifornia92646United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
ID
NCT03843125
Phase
Phase 3
Study Type
Interventional
Last Updated